Kala Bio, Inc. earnings releases KALA

Annual Quarterly

Kala Bio, Inc. last reported quarterly results on Aug 8, 2025, for Q2 FY2025 (the quarter ended Jun 30, 2025): diluted EPS of -$85.64. It usually reports 37–44 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Aug 8, 2025 39 days after quarter end	Q2 FY2025 ended Jun 30, 2025	—	-11 -16.5%	-85.64 -2610.1%
May 14, 2025 44 days after quarter end	Q1 FY2025 ended Mar 31, 2025	—	-9 +24.2%	-70.49 -1579.5%
Nov 12, 2024 43 days after quarter end	Q3 FY2024 ended Sep 30, 2024	—	-9 -2.8%	-1.93 +43.4%
Aug 6, 2024 37 days after quarter end	— ended Jun 30, 2024	—	—	—
May 14, 2024 44 days after quarter end	— ended Mar 31, 2024	—	—	—
Nov 13, 2023 44 days after quarter end	— ended Sep 30, 2023	—	—	—
Aug 4, 2023 35 days after quarter end	— ended Jun 30, 2023	—	—	—
May 9, 2023 39 days after quarter end	— ended Mar 31, 2023	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: KALA (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Arlington, MA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1479419
Former names: KALA BIO, Inc. (until Nov 3, 2026); Kala Pharmaceuticals, Inc. (until Jun 23, 2023)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.